«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:

34

期数:

2017年7

页码:

639-643

栏目:

临床研究

出版日期:

2017-07-05

文章信息/Info

Title:

Effect and safety of compound glycyrrhizin combined with desloratadine tablet and recombinant bovine basic fibroblast growth factor gel in the treatment of facial steroid-dependent dermatitis

作者:

王希香¹; 张信江²; 朱月玲¹; 谢云峰¹; 高国强¹; 刘志梅³

（1.洛阳东方医院皮肤科，河南　洛阳　471003；2.遵义医学院附属医院皮肤科，贵州　遵义　563000；3.遵义医药高等专科学校皮肤性病学教研室，贵州　遵义　563006）

Author(s):

WANG Xi-xiang¹; ZHANG Xin-jiang²; ZHU Yue-ling¹; XIE Yun-feng¹; GAO Guo-qiang¹; LIU Zhi-mei³

（1.Department of Dermatology，Dongfang Hospital of Luoyang City，Luoyang 471003，Henan Province，China；2.Department of Dermatology and Venereology，Affiliated Hospital of Zunyi Medical University，Zunyi 563000，Guizhou Province，China；3.Department of Dermatology，

关键词:

面部激素依赖性皮炎; 复方甘草酸苷片; 重组牛碱性成纤维细胞生长因子凝胶

Keywords:

facial hormone-dependent dermatitis; compound glycyrrhizin tablets; recombinant bovine basic fibroblast growth factor gel

分类号:

R758

DOI:

10.7683/xxyxyxb.2017.07.023

文献标志码:

A

摘要:

目的　评价复方甘草酸苷片联合地氯雷他定片及重组牛碱性成纤维细胞生长因子凝胶治疗面部激素依赖性皮炎的疗效及安全性。方法　选择洛阳东方医院2014年3月至2016年3月收治的116例面部激素依赖性皮炎患者并随机分为观察组和对照组，每组58例。2组患者均每晚1次口服地氯雷他定片5 mg，患处薄层涂抹重组牛碱性成纤维细胞生长因子凝胶，早晚各1次，共12周。观察组患者同时口服复方甘草酸苷片50 mg，每日3次，疗程12周。治疗4、8、12周后及停药4周后观察患者面部症状及体征，并进行评分，计算痊愈率、显效率。结果　治疗4、8、12周后，观察组患者的痊愈率、有效率均显著高于对照组（P<0.05）。治疗前，2组患者的临床症状体征评分总积分及各项临床症状、体征评分比较差异均无统计学意义（P>0.05）。治疗4、8、12周后，2组患者的临床症状体征评分总积分与治疗前比较均显著降低（P<0.05）。治疗8周后，观察组患者的临床症状体征评分总积分较治疗4周后显著下降（P<0.05）；治疗12周后，对照组和观察组患者的临床症状体征评分总积分均较治疗8周后显著下降（P<0.05）。停药后4周，2组患者的临床症状体征评分总积分均较治疗12周后下降（P<0.05）。观察组患者治疗4、8、12周及停药后4周的临床症状体征评分总积分均显著低于对照组（P<0.05）。治疗8、12周后，2组患者色素沉着、表皮萎缩评分与治疗前比较显著降低（P<0.05）。治疗8周后，2组患者红斑、鳞屑、丘疹、脓疱、毛细血管扩张、色素沉着评分与治疗4周后比较显著降低（P<0.05）。治疗12周后，2组患者红斑、鳞屑、丘疹、脓疱、毛细血管扩张评分与治疗8周后比较显著降低（P<0.05）；对照组患者色素沉着评分与治疗4周后比较显著降低（P<0.05）；观察组患者色素沉着、表皮萎缩评分与治疗4、8周后比较显著降低（P<0.05）。治疗4、8、12周后，观察组患者的红斑、鳞屑、丘疹、脓疱各项评分与对照组比较显著降低（P<0.05）。治疗12周后，观察组患者的毛细血管扩张、色素沉着、表皮萎缩评分与对照组比较显著降低（P<0.05）。停药后4周，2组患者的各临床症状、体征评分与治疗12周后比较均显著降低，且显著低于对照组（P<0.05）。观察组有效病例的平均起效时间和痊愈平均时间均显著低于对照组（P<0.05）。观察组患者停药后4周的临床症状体征总积分显著低于对照组（P<0.05）。2组患者总体不良反应发生率比较差异无统计学意义（χ²=0.038，P>0.05）。结论　复方甘草酸苷片可以提高地氯雷他定片及重组牛碱性成纤维细胞生长因子凝胶治疗面部激素依赖性皮炎的疗效。

Abstract:

Objective　To evaluate the effect and safety of compound glycyrrhizin combined with desloratadine tablet and recombinant bovine basic fibroblast growth factor gel in the treatment of facial steroid-dependent dermatitis.Methods　A total of 116 patients with facial hormone-dependent dermatitis were selected from March 2014 to March 2016 in Dongfang Hospital of Luoyang City.The patients were randomly divided into observation group and control group，58 patients in each group.The patients in the two groups were given desloratadine tablet 5 mg orally，once per night；the affected area was coated with recombinant bovine basic fibroblast growth factor gel，once a day for 12 weeks.Based on this，the patients in the observation group were given compound glycyrrhizin tablet 50 mg orally，3 times a day for 12 weeks.The facial symptoms and signs were observed and scored，and the cure rate and excellence rate were calculated at the time points of after 4，8，12 weeks of treatment and 4 weeks after treatment.Results　The cure rate and effective rate in the observation group were significantly higher than those in the control group after 4，8 and 12 weeks of treatment（P<0.05）.There was no significant difference in the total score of clinical symptoms and the scores of every clinical symptom and sign between the two groups before treatment （P>0.05）.The total scores of clinical symptoms and physical signs at the time points of after 4，8，12 weeks of treatment were significantly lower than those before treatment （P<0.05）.The total scores of clinical symptoms and physical signs after 8 weeks of treatment were significantly lower than those after 4 weeks of treatment in the observation group （P<0.05）.The total scores of clinical symptoms and physical signs after 12 weeks of treatment were significantly lower than those after 8 weeks of treatment in the two groups （P<0.05）.The total scores of clinical symptoms and physical signs at the time point of 4 weeks after treatment were significantly lower than those after 12 weeks of treatment in the two groups （P<0.05）.The total scores of clinical symptoms and physical signs in the observation group were significantly lower than those in the control group at the time points of after 4，8，12 weeks of treatment and 4 weeks after treatment （P<0.05）.The scores of pigmentation and epidermal atrophy after 8 and 12 weeks of treatment were significantly lower than those before treatment in the two groups （P<0.05）.The scores of erythema，scales，pimples，pustules，telangiectasis and pigmentation after 8 weeks of treatment were significantly lower than those after 4 weeks of treatment in the two groups （P<0.05）.The scores of erythema，scales，pimples，pustules and telangiectasis after 12 weeks of treatment were significantly lower than those after 8 weeks of treatment in the two groups （P<0.05）.The score of chromatosis after 12 weeks of treatment was significantly lower than that after 4 weeks of treatment in the control group （P<0.05）.The score of chromatosis after 12 weeks of treatment was significantly lower than that after 4 weeks of treatment in the control group （P<0.05）.The scores of chromatosis and atrophy of epidermis after 12 weeks of treatment were significantly lower than those after 4，8 weeks of treatment in the observation group （P<0.05）.The scores of erythema，scales，pimples and pustules in the observation group were significantly lower than those in the control group after 4，8，12 weeks of treatment （P<0.05）.The scores of telangiectasis，chromatosis and atrophy of epidermis in the observation group were significantly lower than those in the control group after 12 weeks of treatment （P<0.05）.The scores of clinical symptoms and signs at the time point of 4 weeks after treatment were significantly lower than those after 12 weeks of treatment in the two groups（P<0.05）.The scores of clinical symptoms and signs in the observation group were significantly lower than those in the control group at the time point of 4 weeks after treatment （P<0.05）.The average onset time and recovery time of the effective cases in the observation group were significantly lower than those in the control group （P<0.05）.The total score of clinical symptoms and signs in the observation group was significantly lower than that in the control group at the time point of 4 weeks after treatment （P<0.05）.There was no significant difference in the incidence of adverse reactions between the two groups （χ²=0.038，P>0.05）.Conclusion　Compound glycyrrhizin tablet can improve the curative effect of desloratadine tablet and recombinant bovine basic fibroblast growth factor gel in the treatment of facial hormone-dependent dermatitis.

常用功能

更新日期/Last Update: 2017-07-05